Filter Results:
(482)
Show Results For
- All HBS Web (482)
- Faculty Publications (365)
Show Results For
- All HBS Web (482)
- Faculty Publications (365)
- October 2001 (Revised April 2002)
- Case
Calgene, Inc.
By: Ray A. Goldberg and John T. Gourville
In 1993, Calgene is on the verge of introducing the world's first genetically engineered plant product--a tomato will taste better and stay fresh longer. At the same time, it is using biotechnology to produce improved plant products for the cottonseed and the... View Details
Keywords: Information Technology; Marketing Strategy; Market Entry and Exit; Product Launch; Innovation Strategy; Social Issues; Production; Problems and Challenges; Biotechnology Industry; Biotechnology Industry
Goldberg, Ray A., and John T. Gourville. "Calgene, Inc." Harvard Business School Case 502-041, October 2001. (Revised April 2002.)
- 13 Jan 2003
- Research & Ideas
Making Biotech Work as a Business
create safer and more effective treatments and, of course, reap profits—industry executives, like hopeful patients, still restlessly wait for relief. Given its scientific potential, said Pisano, biotech continues to bump against several economic barriers that need to... View Details
- October 2002
- Case
A Father's Love: Novazyme Pharmaceuticals, Inc.
By: Richard M.J. Bohmer and Bradley Campbell
John Crowley, CEO of Novazyme Pharmaceuticals, a start-up biotechnology firm developing an orphan drug to treat a rare lysosomal storage disorder from which his children suffer, must choose between a partnership and a buyout to have sufficient funds and support to get... View Details
Keywords: Technological Innovation; Business Startups; Partners and Partnerships; Financing and Loans; Governing Rules, Regulations, and Reforms; Sales; Price; Product Development; Motivation and Incentives; Decision Choices and Conditions; Biotechnology Industry; Biotechnology Industry
Bohmer, Richard M.J., and Bradley Campbell. "A Father's Love: Novazyme Pharmaceuticals, Inc." Harvard Business School Case 603-048, October 2002.
- 2006
- Book
Science Business: The Promise, the Reality, and the Future of Biotech
By: Gary P. Pisano
Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details
Pisano, Gary P. Science Business: The Promise, the Reality, and the Future of Biotech. Boston: Harvard Business School Press, 2006.
- February 2010 (Revised September 2011)
- Case
Roche's Acquisition of Genentech
By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; Switzerland
Baldwin, Carliss Y., Bo Becker, and Vincent Marie Dessain. "Roche's Acquisition of Genentech." Harvard Business School Case 210-040, February 2010. (Revised September 2011.)
- March 2022
- Case
Tensions at SearchLight Cures
By: Laura Huang and Sarah Mehta
This general experience case tells the story of SearchLight Cures, a fictional biotechnology startup. Having discovered a new therapy for a rare disease, the company’s co-founders find themselves at an impasse over a pricing disagreement. View Details
Keywords: Business Ventures; Business Growth and Maturation; Business Startups; Communication; Interpersonal Communication; Values and Beliefs; Management; Negotiation; Relationships; Partners and Partnerships; Science; Biotechnology Industry; United States; California; San Francisco
Huang, Laura, and Sarah Mehta. "Tensions at SearchLight Cures." Harvard Business School Case 422-059, March 2022.
- June 2005 (Revised July 2006)
- Background Note
Note on the Convergence Between Genomics & Information Technology
By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha
Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in... View Details
Keywords: Genetics; Information Technology; Business Model; Disruptive Innovation; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Yoffie, David B., Dharmesh M Mehta, and Rachel Sha. "Note on the Convergence Between Genomics & Information Technology." Harvard Business School Background Note 705-500, June 2005. (Revised July 2006.)
- October 2001 (Revised May 2002)
- Case
Proteome Systems Limited
A Sydney-based biotechnology company is attempting to enter the fast-growing proteomics area. This case highlights choices in business design and changes in these over time. Also addresses issues in geographic location. View Details
Keywords: Organizational Change and Adaptation; Geographic Location; Market Entry and Exit; Biotechnology Industry; Sydney
West, Jonathan, and Mona Ashiya. "Proteome Systems Limited." Harvard Business School Case 602-039, October 2001. (Revised May 2002.)
- September 2020 (Revised January 2021)
- Case
Catalys Pacific
In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After... View Details
Keywords: Pharmaceutical Companies; Biotech; Health Care; Entrepreneur; Innovation; International Business; Entrepreneurial Finance; Entrepreneurship; Finance; Innovation Strategy; Venture Capital; Strategy; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Pharmaceutical Industry; Tokyo
Krieger, Joshua Lev. "Catalys Pacific." Harvard Business School Case 821-035, September 2020. (Revised January 2021.)
- September 2019
- Case
Nimbus Therapeutics
By: Peter Barrett, Karim Lakhani and Julia Kelley
This case focuses on Nimbus Therapeutics, a biotechnology startup based in Cambridge, Massachusetts, as its leadership team tries to determine the company’s long-term strategy. The startup’s founders structured Nimbus as a limited liability company, which has given it... View Details
Barrett, Peter, Karim Lakhani, and Julia Kelley. "Nimbus Therapeutics." Harvard Business School Case 620-016, September 2019.
- November 2008
- Case
Adnexus Therapeutics, Inc.: Considering the Exit
By: Vicki L. Sato and Rachel Gordon
Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO. View Details
Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Entrepreneurship; Initial Public Offering; Corporate Strategy; Biotechnology Industry
Sato, Vicki L., and Rachel Gordon. "Adnexus Therapeutics, Inc.: Considering the Exit." Harvard Business School Case 609-015, November 2008.
- June 1997 (Revised October 2001)
- Case
Elliot Lebowitz
By: Paul A. Gompers and Alexander Tsai
Elliot Lebowitz, president and CEO of BioTransplant, must decide on a strategy for this young biotechnology start-up. Among the issues to be resolved are focus of research and search for strategic alliance partners. View Details
Keywords: Alliances; Research; Business Startups; Management Teams; Business Strategy; Biotechnology Industry; United States
Gompers, Paul A., and Alexander Tsai. "Elliot Lebowitz." Harvard Business School Case 297-094, June 1997. (Revised October 2001.)
- December 1992 (Revised September 1996)
- Case
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details
Keywords: Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Biotechnology Industry; Biotechnology Industry; United States
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (Abridged)." Harvard Business School Case 293-087, December 1992. (Revised September 1996.)
- June 1997 (Revised March 2001)
- Case
Genset Initial Public Offering (A)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research. View Details
Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (A)." Harvard Business School Case 297-096, June 1997. (Revised March 2001.)
- October 1992 (Revised November 1997)
- Case
ImmuLogic Pharmaceutical Corporation (A): March 1991
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details
Keywords: Decisions; Entrepreneurship; Venture Capital; Banks and Banking; Initial Public Offering; Going Public; Perspective; Valuation; Biotechnology Industry; Biotechnology Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (A): March 1991." Harvard Business School Case 293-066, October 1992. (Revised November 1997.)
- January 2007
- Background Note
Note on Biotech Business Development
By: Richard G. Hamermesh and Robert F. Higgins
Describes the business development process in biotechnology companies. Topics covered include: participants in the licensing process and their interests, the major steps in the licensing process, the terms that are part of most agreements, and the most contentious... View Details
Keywords: Agreements and Arrangements; Entrepreneurship; Intellectual Property; Biotechnology Industry
Hamermesh, Richard G., and Robert F. Higgins. "Note on Biotech Business Development." Harvard Business School Background Note 807-032, January 2007.
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
- March 2016
- Article
Environmental Demands and the Emergence of Social Structure: Technological Dynamism and Interorganizational Network Forms
By: Adam Tatarynowicz, Maxim Sytch and Ranjay Gulati
This study investigates the origins of variation in the structures of interorganizational networks across industries. We combine empirical analyses of existing interorganizational networks in six industries with an agent-based simulation model of network emergence.... View Details
Keywords: Interorganizatonal Relationships; Social Networks; Network Emergence; Interorganizational Networks; Information Technology; Networks; Organizational Structure; Social and Collaborative Networks; Social Media
Tatarynowicz, Adam, Maxim Sytch, and Ranjay Gulati. "Environmental Demands and the Emergence of Social Structure: Technological Dynamism and Interorganizational Network Forms." Administrative Science Quarterly 61, no. 1 (March 2016): 52–86.
Gary P. Pisano
Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details
- November 1991 (Revised April 1994)
- Case
Nucleon, Inc.
By: Gary P. Pisano
Nucleon is a small biotechnology company whose first potential product is about to enter clinical testing. Before Nucleon can begin clinical trials, however, its management must decide how and where to manufacture the product. Three options are being contemplated: 1)... View Details
Keywords: Factories, Labs, and Plants; Entrepreneurship; Health Testing and Trials; Rights; Product Development; Production; Partners and Partnerships; Research and Development; Biotechnology Industry
Pisano, Gary P. "Nucleon, Inc." Harvard Business School Case 692-041, November 1991. (Revised April 1994.)